EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access

Survival outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from gastric cancer: a systematic review

Claramae Shulyn Chia, Ramakrishnan Ayloor Seshadri, Vahan Kepenekian, Delphine Vaudoyer, Guillaume Passot, Olivier Glehen

Pleura and Peritoneum · 2016

DOI: 10.1515/pp-2016-0010 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pleura and Peritoneum, 2016. Verfasst von Claramae Shulyn Chia und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Surgical Oncology, National Cancer Centre Singapore, Singapore. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The current treatment of choice for peritoneal carcinomatosis from gastric cancer is systemic chemotherapy. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is a new aggressive form of loco-regional treatment that is currently being used in pseudomyxoma peritoneii, peritoneal mesothelioma and peritoneal carcinomatosis from colorectal cancer. It is still under investigation for its use in gastric cancer.

Methods

The literature between 1970 and 2016 was surveyed systematically through a review of published studies on the treatment outcomes of CRS and HIPEC for peritoneal carcinomatosis from gastric cancer.

Results

Seventeen studies were included in this review. The median survival for all patients ranged from 6.6 to 15.8 months. The 5-years overall survival ranged from 6 to 31%. For patients with complete cytoreduction, the median survival was 11.2 to 43.4 months and the 5-years overall survival was 13 % to 23%. Important prognostic factors were found to be a low peritoneal carcarcinomatosis index (PCI) score and the completeness of cytoreduction.

Conclusion

The current evidence suggests that CRS and HIPEC has a role to play in the treatment of peritoneal carcinomatosis from gastric cancer. Long term survival has been shown for a select group of patients. However, further studies are needed to validate these results.

Schlagwörter

Stichwörter der Autor:innen

HIPECgastric cancerperitoneal carcinomatosis

Autor:innen und Institutionen

  • Division of Surgical Oncology, National Cancer Centre Singapore, Singapore.
  • Department of Surgical Oncology, Cancer Institute (WIA), Chennai, India.

Zitieren

APA

Chia, C. S., Seshadri, R. A., Kepenekian, V., Vaudoyer, D., Passot, G., & Glehen, O. (2016). Survival outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from gastric cancer: a systematic review. Pleura and Peritoneum. https://doi.org/10.1515/pp-2016-0010

Vancouver

Chia CS, Seshadri RA, Kepenekian V, Vaudoyer D, Passot G, Glehen O. Survival outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from gastric cancer: a systematic review. Pleura and Peritoneum. 2016. doi:10.1515/pp-2016-0010

BibTeX
@article{Chia2016,
  author = {Chia, Claramae Shulyn and Seshadri, Ramakrishnan Ayloor and Kepenekian, Vahan and Vaudoyer, Delphine and Passot, Guillaume and Glehen, Olivier},
  title = {Survival outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from gastric cancer: a systematic review},
  journal = {Pleura and Peritoneum},
  year = {2016},
  doi = {10.1515/pp-2016-0010}
}
Kostenlos starten →